RBC Capital maintains United Therapeutics at Outperform
RBC Capital maintained its Outperform rating on United Therapeutics and raised its price target to $708 from $677.
Story updates
03:08:42 PM UTC
SquawkNews
United Therapeutics Price Target Raised to $708.00/Share From $677.00 by RBC Capital